When was Evive Biotech founded?

Evive Biotech was founded in 2004.

Where is Evive Biotech located?

Evive Biotech is headquartered in Singapore, Singapore. It is registered at 150 BEACH ROAD #32-05/08 GATEWAY WEST SINGAPORE 189720.

Which legal entities is Evive Biotech associated with?

Evive Biotech is associated with EVIVE BIOTECHNOLOGY SINGAPORE PTE. LTD..

How many employees does Evive Biotech have?

As of Jul 01, 2024, the latest employee count at Evive Biotech is 51.

Is Evive Biotech a funded company?

Evive Biotech is a funded company, having raised a total of $***** in its 1st and only funding round.

Where does Evive Biotech rank among its competitors?

Evive Biotech ranks 1818th amongst 3493 active competitors, of which 1200 are funded. It stands 11th in terms of total funding among its competitors. The most recent competitor to raise funding was Moderna, which secured $590M in Jan, 2025.

Who are the top competitors of Evive Biotech?

Evive Biotech's top competitors include Jazz Pharmaceuticals, Moderna and Sana Biotechnology. Among them, Moderna secured the most recent funding round in January, 2025.

Evive Biotech - 2026 Company Profile, Team & Competitors

Evive Biotech is an unfunded company based in Singapore (Singapore), founded in 2004. It operates as a Developers of biologics for treating oncology and inflammatory disorders. Evive Biotech has not raised any funding yet. The company has 3493 active competitors, including 1200 funded and 841 that have exited. Its top competitors include companies like Jazz Pharmaceuticals, Moderna and Sana Biotechnology.

Company Details

Evive Biotech is the developer of biologics for treating oncology and inflammatory disorders. The company develops a portfolio of novel drugs by using its two proprietary technology platforms, DiKine and ITab. The pipeline products are in phase 3 of preclinical research and based on G-CSF fusion protein. The flagship products are A337 (phase 1) for solid tumors, A3109 (phase 1) for B-cell leukemia among others.

Website: www.evivebiotech.com
Email ID: *****@evivebiotech.com
Phone Number: +65 **********
Registered Address: 150 BEACH ROAD #32-05/08 GATEWAY WEST SINGAPORE 189720

Key Metrics

Founded Year

2004

Location

Singapore, Singapore

Stage

Unfunded

Ranked

1818^th among 3493 active competitors

Employee Count

51 as on Jul 01, 2024

Similar Companies

Jazz Pharmaceuticals & 3348 more

View Evive Biotech's full profile

Evive Biotech is associated with 1 legal entity given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
EVIVE BIOTECHNOLOGY SINGAPORE PTE. LTD. CIN: 202024734N , Singapore, Active	Dec 31, 2003	-	-

Evive Biotech has not raised any funding rounds yet.

Evive Biotech's employee count trend

Evive Biotech has 51 employees as of Jul 24. Here is Evive Biotech's employee count trend over the years:

Uncover Evive Biotech's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Evive Biotech include Jazz Pharmaceuticals, Moderna and Sana Biotechnology. Here is the list of Top 10 competitors of Evive Biotech, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Jazz Pharmaceuticals 2003, Dublin (Ireland), Public	Developer of novel biopharmaceutical medicines for unmet medical needs	$265M	Versant Ventures, Prospect Venture Partners ... & 14 others	82/100
2nd	Moderna 2010, Cambridge (United States), Public	Developer of mRNA-based therapeutics for a wide range of diseases	$2.78B	Merck, Astrazeneca & 31 others	80/100
3rd	Sana Biotechnology 2018, Seattle (United States), Public	Developer of genetically engineered cell therapies for multiple disorders	$821M	Bezos Expeditions, F-Prime Capital & 17 others	75/100
4th	C4 Therapeutics 2016, Cambridge (United States), Public	Developer of small molecule drugs for treating cancer	$223M	Cobro Ventures, Perceptive Advisors & 27 others	74/100
5th	Blueprint Medicines 2008, Cambridge (United States), Acquired	Developer of selective kinase inhibitors for patients with genomically defined cancers	$115M	Third Rock Ventures, Nextech Invest & 20 others	73/100
6th	Kronos Bio 2017, San Mateo (United States), Acquired	Developer of small molecule based therapeutics for cancer treatment	$271M	Omega Funds, Vida Ventures & 18 others	72/100
7th	Regeneron Pharmaceuticals 1988, Tarrytown (United States), Public	Developer of antibodies for the treatment of cancer, eye diseases, inflammatory diseases & others	-	Kaccelerator, BB Biotech & 7 others	72/100
8th	BeiGene 2010, Cambridge (United States), Public	Developer of targeted and immune-oncology drugs against cancer	$172M	Hillhouse, Boxer Capital & 13 others	72/100
9th	MacroGenics 2000, Rockville (United States), Public	Developer of novel biologics for the treatment of autoimmune disorders, cancer and infectious disease	$126M	Nextech Venture, Ventures West & 29 others	72/100
10th	ADMA Biologics 2005, Ramsey (United States), Public	Biopharmaceutical company innovating plasma-derived therapeutics for immune deficiencies and infectious diseases	$17.6M	Aisling Capital, Burrill and Company & 4 others	71/100
1818th	Evive Biotech 2004, Singapore (Singapore), Unfunded	Developers of biologics for treating oncology and inflammatory disorders	-	-	31/100